Treatment of splenic marginal zone lymphoma: should splenectomy be abandoned?
C Kalpadakis, GA Pangalis… - Leukemia & …, 2014 - Taylor & Francis
Splenic marginal zone lymphoma (SMZL) is a rare chronic B-cell lymphoproliferative
disorder recognized as a distinct entity in the World Health Organization (WHO) …
disorder recognized as a distinct entity in the World Health Organization (WHO) …
Treatment of splenic marginal zone lymphoma
Splenic marginal zone lymphoma (SMZL) is a distinct lymphoma entity characterized by an
indolent clinical course and prolonged survival. Treatment is not standardized, since there …
indolent clinical course and prolonged survival. Treatment is not standardized, since there …
Treatment of splenic marginal zone lymphoma with rituximab monotherapy: progress report and comparison with splenectomy
Background. Treatment of splenic marginal zone lymphoma (SMZL) patients is not
standardized. Recent data suggest that rituximab is highly effective and could be considered …
standardized. Recent data suggest that rituximab is highly effective and could be considered …
Treatment of splenic marginal zone lymphoma: splenectomy versus rituximab
M Bennett, GP Schechter - Seminars in hematology, 2010 - Elsevier
Splenic marginal zone lymphoma (SMZL) is an uncommon indolent B-cell lymphoma
causing marked splenic enlargement with CD20-rich lymphoma cells infiltrating blood and …
causing marked splenic enlargement with CD20-rich lymphoma cells infiltrating blood and …
Rituximab, used alone or in combination, is superior to other treatment modalities in splenic marginal zone lymphoma
M Else, A Marín‐Niebla, F de la Cruz… - British journal of …, 2012 - Wiley Online Library
Splenic marginal zone lymphoma (SMZL) is a rare B‐cell malignancy, with no standard
treatment other than splenectomy. Rituximab has shown encouraging results. We therefore …
treatment other than splenectomy. Rituximab has shown encouraging results. We therefore …
Splenic marginal zone lymphoma: disease features and management
E Matutes - Expert review of hematology, 2013 - Taylor & Francis
Splenic marginal zone lymphoma (SMZL) is a lymphoma recognized as a distinct entity in
the WHO classification of the lymphoid tumors. SMZL probably results from the expansion of …
the WHO classification of the lymphoid tumors. SMZL probably results from the expansion of …
Outcomes in splenic marginal zone lymphoma: analysis of 107 patients treated in British Columbia
KH Xing, A Kahlon, BF Skinnider… - British journal of …, 2015 - Wiley Online Library
Splenic marginal zone lymphoma (SMZL) accounts for less than 2% of all non‐Hodgkin
lymphomas. We identified 107 cases diagnosed with SMZL between 1985 and 2012 from …
lymphomas. We identified 107 cases diagnosed with SMZL between 1985 and 2012 from …
Rituximab monotherapy is highly effective in splenic marginal zone lymphoma
C Kalpadakis, GA Pangalis… - Hematological …, 2007 - Wiley Online Library
Splenectomy has traditionally been considered as a standard first line treatment for splenic
marginal zone lymphoma (SMZL) conferring a survival advantage over chemotherapy …
marginal zone lymphoma (SMZL) conferring a survival advantage over chemotherapy …
Should rituximab replace splenectomy in the management of splenic marginal zone lymphoma?
Background SMZL is a relatively rare low grade B-cell lymphoma, characterized usually by
an indolent clinical behavior. Since there is no prospective randomized trials to establish the …
an indolent clinical behavior. Since there is no prospective randomized trials to establish the …
Rituximab with cyclophosphamide, vincristine, non-pegylated liposomal doxorubicin and prednisone as first-line treatment for splenic marginal zone lymphoma: a …
Rituximab® provides high response rates and effective disease palliation in patients with
splenic marginal zone lymphoma (SMZL). We conducted a phase II trial in patients with …
splenic marginal zone lymphoma (SMZL). We conducted a phase II trial in patients with …